Tirzepatide
Mounjaro · Zepbound · GIP/GLP-1 dual agonist · 替尔泊肽
Think of it as a fitness coach for your metabolism.
Tirzepatide is like having a metabolism whisperer. It tells your body to release insulin more effectively when your blood sugar levels rise, like a gentle nudge to keep things balanced. This can help manage those pesky sugar spikes after meals.
But that's not all. Tirzepatide also sends signals to your brain that you're fuller sooner, making those extra helpings less tempting. It even takes its time moving food through your stomach, so you feel satisfied longer. Think of it as subtle encouragement to eat less without feeling deprived.
This dual-action approach has shown impressive results in shedding pounds and improving metabolic health markers like blood pressure and cholesterol. It's like giving your body a little extra help in staying on track, especially if weight management has been an uphill battle.
Who it's for
- Busy professionals looking to manage their weight and health more effectively.
- Fitness enthusiasts wanting to optimize their metabolic health.
- Individuals struggling with post-meal sugar spikes.
- People seeking an additional tool in their weight loss journey.
Probably not for you if…
- Those unwilling to commit to regular injections.
- Individuals looking for a quick fix without lifestyle changes.
- People who prefer natural or non-prescription solutions.
Editorial summary for research context · Not medical advice
Mechanism of Action
Tirzepatide is a synthetic dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. The dual mechanism enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. It is FDA-approved for type 2 diabetes and chronic weight management under the brand names Mounjaro and Zepbound — only the prescribed, pharmaceutical-grade product is appropriate for human use.
Researched Benefits
Glycemic control
Phase 3 SURPASS trials demonstrated HbA1c reductions of ~2.0–2.4 percentage points at higher doses.
- [Rosenstock et al. 2021 (SURPASS-1)]
Weight reduction
SURMOUNT-1 trial reported mean weight loss of ~20% at the 15mg weekly dose over 72 weeks.
- [Jastreboff et al. 2022]
Cardiometabolic markers
Improvements in blood pressure, lipid profile, and waist circumference reported across pivotal trials.
Research Protocols
The following dosing ranges have appeared in published research protocols. Presented for informational purposes only — not a recommendation for human use.
Clinical titration (reference only — prescription required)
- Dosage
- 2.5 mg
- Frequency
- once weekly
- Timing
- same day each week
- Cycle
- 4 weeks
Clinical trials titrate upward every 4 weeks to maintenance doses of 5/10/15mg. Only prescribed use is appropriate.
Reported Side Effects
- Gastrointestinal: nausea, diarrhea, vomiting, constipation (typically titration-related)
- Injection-site reactions
- Hypoglycemia risk when combined with sulfonylureas or insulin
- Rare: pancreatitis, gallbladder events
- Boxed warning: thyroid C-cell tumor risk observed in rodents
Contraindications
- Personal or family history of medullary thyroid carcinoma
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy
- History of severe gastroparesis
Stacking Partners
Peptides commonly paired with Tirzepatide in published research and protocol write-ups.
Vendor Pricing
Stacked earns a commission on purchases via these links. It does not influence our Trust Scores.
Gear + Companions
Reconstitution supplies and research-backed supplement companions for Tirzepatide. Editorial picks only — we earn a commission through Amazon on the click, no sponsorship.
Gear you'll need
· Reconstitution + storage essentialsBacteriostatic Water 30mL (0.9% Benzyl Alcohol)
Empower Pharmacy / generic medical supply
Reconstitutes every lyophilized peptide. 28-day viability refrigerated.
Insulin Syringes 31G × 5/16" × 0.5mL (100 count)
EasyTouch
31G × 0.5mL insulin syringes — the default size for sub-0.25mL peptide doses.
Alcohol Prep Pads (Sterile, 200 count)
Dynarex
Sterile 70% IPA prep pads — one per vial stopper + one per injection site.
1-Quart Sharps Disposal Container
BD / Becton Dickinson
FDA-cleared sharps container — pharmacies won't accept improvised disposal.
Stacks well with
· Supplement companions — independent evidence, not sponsoredLMNT Electrolyte Drink Mix Variety Pack (30 sticks)
LMNT
GLP-1 agonism suppresses thirst — dehydration + electrolyte drop is the #1 source of the 'GLP-1 flu' complaint. LMNT targets that gap directly.
Psyllium Husk Fiber Capsules (500 ct)
NOW Foods
Constipation is the most-reported GLP-1 side effect. Daily soluble fiber addresses it without blunting the appetite effect.
Whey Protein Isolate 5 lb (Grass-Fed, Unflavored)
NAKED Nutrition
Appetite suppression tanks protein intake if you don't actively defend it — protein powder is the cheapest floor against lean-mass loss.
Further reading
· Context + frameworks — full-length on the topicOutlive: The Science & Art of Longevity (Peter Attia MD)
Peter Attia
Attia's metabolic-health framing provides the context GLP-1 research fits into.
As an Amazon Associate we earn from qualifying purchases · Disclosed per FTC guidelines
Top Videos
Curated from YouTube — refreshed weekly. Stacked doesn't host or endorse external content.
5:45The Best MOUNJARO Alternative (Without the Side Effects) - Dr. Berg
Dr. Eric Berg DC
461.9K views · 5:45 · 2 years ago
4:41What happens to your body when you stop taking weight-loss drugs l GMA
Good Morning America
434.8K views · 4:41 · 2 years ago
15:11Semaglutide/Tirzepatide Users: 11 Things to Avoid! // Dr. G Explains
Dr. G's Lifestyle Medicine Network
346.7K views · 15:11 · 2 years ago
7:42Mounjaro (tirzepatide): The newest diabetes and obesity medication (explanation and overview)
Christopher McGowan, MD
310.1K views · 7:42 · 3 years ago
5:04How does Zepbound (tirzepatide) compare to Wegovy (semaglutide)?
Christopher McGowan, MD
198.6K views · 5:04 · 2 years ago
Research Papers
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff AM, et al. · New England Journal of Medicine · 2022
PubMed 35658024 →Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1)
Rosenstock J, et al. · The Lancet · 2021
PubMed 34186022 →